about
Daclizumab for relapsing remitting multiple sclerosisDaclizumab therapy for multiple sclerosisInfection risk in patients on multiple sclerosis therapeutics.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Multiple sclerosis treatment and infectious issues: update 2013.
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Daclizumab for relapsing remitting multiple sclerosis
@ast
Daclizumab for relapsing remitting multiple sclerosis
@en
Daclizumab for relapsing remitting multiple sclerosis
@en-gb
Daclizumab for relapsing remitting multiple sclerosis
@nl
type
label
Daclizumab for relapsing remitting multiple sclerosis
@ast
Daclizumab for relapsing remitting multiple sclerosis
@en
Daclizumab for relapsing remitting multiple sclerosis
@en-gb
Daclizumab for relapsing remitting multiple sclerosis
@nl
prefLabel
Daclizumab for relapsing remitting multiple sclerosis
@ast
Daclizumab for relapsing remitting multiple sclerosis
@en
Daclizumab for relapsing remitting multiple sclerosis
@en-gb
Daclizumab for relapsing remitting multiple sclerosis
@nl
P2093
P2860
P1476
Daclizumab for relapsing remitting multiple sclerosis
@en
P2093
Luning Wang
Si-Yan Zhan
Yinyin Xia
P2860
P356
10.1002/14651858.CD008127.PUB3
P577
2012-04-18T00:00:00Z